Svenska biotechbolag i samarbete om biologiska läkemedel

AAX Biotech och Toxotech har ingått ett strategiskt samarbete för att utveckla nya biologiska läkemedel.

The vaccine has saved 94 million lives – but measles is spreading again

A disease we once believed belonged to the past is now resurging in both Europe and the United States. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.

Licensavtal ska ge Roche nya vägar in i hjärnan

Läkemedelsbolaget Roche ska testa ett nytt sätt att transportera läkemedel till hjärnan – med hjälp av transportmolekyler från Bostonbaserade Manifold Bio.

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever during the retreat from Russia.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 15 major markets — one more than its closest rival, Eli Lilly’s Kisunla.

Swedish life science is growing – but capital is not keeping up

The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted companies are weak.

A cluster contribution to European life science innovation and competitiveness?

Solnabolag i samarbete med Daiichi Sankyo

AAX Biotech inleder ett samarbete med japanska Daiichi Sankyo inom utveckling av antikroppsterapier.

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain.

Lundbeck presenterar första behandlingen mot MSA

Danska läkemedelsbolaget Lundbeck har utvecklat antikroppen amlenetug, som kan innebära den första behandling av multipel systematrofi (MSA).

Sarah Lidé: ”Artificial intelligence must not replace authentic interactions”

Artificial intelligence must never become a replacement for authentic, even if messy, interactions with our fellow humankind, Sarah Lifé, Deputy CEO at Medicon Village Innovation, writes in a column.

Grönt ljus för Gesyntas endometriosstudie i Storbritannien – ”Ett stort steg”

Gesynta Pharma har fått klartecken i Storbritannien för att inleda en fas II-studie med sin läkemedelskandidat inom endometrios.

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Heart Monitoring in Breast Cancer – Essential or Excessive?

Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.

Novo Nordisk tells staff to return to office

At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate decision-making and improve commercial execution as competition in the obesity drug market intensifies.

Eli Lilly Recruits Leading Swedish Researcher Kaj Blennow to Head Alzheimer’s Project

Eli Lilly recruits Kaj Blennow, leading Alzheimer’s researcher, as VP of neuroscience biomarker development.

Digitalt lyft för Life Science Sweden och resten av Nordiske Medier

Life Science Sweden är en av många branschtidningar som ges ut av B2B-förlaget Nordiske Medier, som nu kan erbjuda alla läsare en mer modern och användarvänlig plattform.

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pivotal CAR-T trial.

Allogene avvecklar experimentell antikropp efter dödsfall

Det amerikanska bioteknikbolaget Allogene Therapeutics stoppar helt användningen av sin experimentella antikropp ALLO-647 efter ett dödsfall i bolagets avgörande CAR-T-studie.

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company will develop treatments for autoimmune diseases where there is currently a lack of effective therapies.

Positivt USA-besked om Alzecures smärtpreparat

Alzecure har beviljats särläkemedelsstatus i USA för smärtpreparatet ACD440.

AZ:s antikroppskonjugat godkänd för ytterligare cancerform

Ett nytt läkemedel mot avancerad icke-småcellig lungcancer har godkänts i USA. Det handlar om Datroway, som tagits fram av AstraZeneca och japanska Daiichi Sankyo.

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Södertörn District Court in Huddinge, south of Stockholm.

Topp 50: Här är Sveriges högst rankade medicinforskare

Kaj Blennow, Tomas Hökfelt och Anders Björklund toppar listan över svenska forskare med störst vetenskapligt genomslag inom det medicinska forskningsfältet. Här är de 50 översta svenska namnen på 2025 års lista.